Injective price outlook: Downward momentum limits rebound potential
Injective (INJ) is trading at $6.64, down 7.79% on the day. The price sits below its key short- and medium-term moving averages, while remaining above its longer-term trend indicator.
Highlights
- Injective will introduce the Veyra Mainnet Upgrade to enable institutional adoption and support tokenized financial products.
- The network development targets expanded use cases for institutional and traditional finance engagement with real-world asset markets.
- INJ trades below key moving averages with most momentum indicators negative, projecting a high probability of further declines toward the $6.22 to $7.06 range.
Institutional support expands as mainnet upgrade counters selling pressure
The Injective team has announced the upcoming Veyra Mainnet Upgrade, introducing features intended to support institutional adoption, real-world asset markets, and new classes of tokenized financial products, according to Cryptowisser. This protocol development aims to broaden the platform's functionality and offers potential for expanded use cases among institutional and traditional finance participants. These enhancements represent ongoing investment in network capabilities, though price action has remained under broader selling pressure.
Momentum remains bearish as resistance intensifies near key moving averages
INJ is currently positioned below the MA-20 and MA-50, reflecting near-term and medium-term resistance from sellers, but continues to trade above the MA-200, which now acts as longer-term support. The Ichimoku Kijun at $6.95 sits as immediate resistance for any attempted price recovery. Momentum indicators show MACD and ADX in Sell mode, while the Awesome Oscillator also signals further downside; Bull/Bear Power remains negative, underscoring strong intraday selling momentum. RSI registers as neutral, but both Stoch RSI and CCI are deeply oversold, indicating that downside momentum could be losing steam and a short-term rebound risk is present.
Downside risk persists as volatility tempers potential rebound
Short-term expectations for INJ call for continued high volatility, with price likely consolidating between $6.22 and $7.06 in the next two to three trading days. The probability of a break lower remains significantly elevated versus the likelihood of a sustained reversal. A move above $6.95 would be required to shift sentiment toward a potential bullish scenario, while a decline through $6.22 could trigger further selling within the typical volatility band for this asset.
Earlier, analysts noted that Injective was contending with persistent volatility and a modest downside bias, despite ongoing protocol upgrades and strong community support. The current analysis deepens this view, as technical pressures remain heightened and volatility is expected to persist, with the $6.22 level now emerging as a critical threshold for further downside risk.